Brief: Actuate Therapeutics Highlights Survival Benefit In Metastatic Pancreatic Cancer Patient Populations
24/06/2025 14:17
June 24 (Reuters) - Actuate Therapeutics Inc ACTU.O: ACTUATE THERAPEUTICS HIGHLIGHTS SIGNIFICANT AND SUSTAINED SURVIVAL BENEFIT IN KEY METASTATIC PANCREATIC CANCER PATIENT POPULATIONS IN PHASE 2 ELRAGLUSIB TRIAL ACTUATE THERAPEUTICS INC - ELRAGLUSIB PLUS GNP SHOWS NEAR DOUBLING OF 1-YEAR OS Source text: ID:nGNX84LPHV Further company coverage: ACTU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsHealth Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing
Brief: Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial
Brief: Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing